169 related articles for article (PubMed ID: 38561819)
1. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
3. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
[TBL] [Abstract][Full Text] [Related]
4. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
[TBL] [Abstract][Full Text] [Related]
5. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
Romeo M; Gil-Martín M; Gaba L; Teruel I; Taus Á; Fina C; Masvidal M; Murata P; Fernández-Plana J; Martínez A; Pérez C; García Y; Rodriguez V; Cros S; Parera M; Zanui M; Catot S; Pardo B; Plaja A; Esteve A; Barretina-Ginesta MP
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139574
[TBL] [Abstract][Full Text] [Related]
8. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
Valenza C; Trapani D; Gandini S; Sposetti C; Boscolo Bielo L; Marra A; Giarratano T; Favero D; Cortesi L; Moscetti L; Pistelli M; Berardi R; Zambelli A; Lambertini M; Del Mastro L; Guarneri V; Vernieri C; Curigliano G
Eur J Cancer; 2023 Sep; 190():112944. PubMed ID: 37437366
[TBL] [Abstract][Full Text] [Related]
10. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
11. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
[TBL] [Abstract][Full Text] [Related]
12. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
Sivakumaran T; Krasovitsky M; Freimund A; Lee YC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G
Int J Gynecol Cancer; 2022 Jul; 32(7):906-912. PubMed ID: 35321889
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; de Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB
Clin Cancer Res; 2013 Oct; 19(19):5485-93. PubMed ID: 23922302
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
Gu X; Shi Z; Shao L; Zhang Y; Zhang Y; Song Z; Wang W; Lou G
BMC Cancer; 2022 May; 22(1):576. PubMed ID: 35606756
[TBL] [Abstract][Full Text] [Related]
19. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
20. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
